PRA Health Sciences, Inc. (NASDAQ:PRAH) is reporting third quarter financial results on Wednesday 4th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, PRAH is expected to report 3Q20 income of $ 1.12 per share from revenue of $ 764.98 million.
For the full year, analysts anticipate top line of $ 3094.68 million, while looking forward to income of $ 4.43 per share bottom line.
The Company Outlook
Earnings for 3Q20 are anticipated in a range of $ 1.09 ~ $ 1.19 per share, while revenues are expected in a range of $ 754.00 million ~ $ 784.00 million
Full Year 2020 topline are forecasted in a range of$ 3,070.00 million ~ $ 3,130.00 million, where as bottomline are predicted in a range of $ 4.35 ~ $ 4.55 per share
Click Here For More Historical Outlooks Of PRA Health Sciences, Inc.
Previous Quarter Performance
PRA Health Sciences, Inc. unfold income for the second quarter of $ 0.86 per share, from the revenue of $ 729.89 million. The quarterly earnings declined 29.51 percent while revenues decreased 4.38 percent compared with the same quarter last year.
Street analysts expected PRA Health Sciences, Inc. to report income of $ 0.83 per share on revenue of $ 716.72 million for the second quarter. The bottom line results beat street analysts by $ 0.03 or 3.61 percent, at the same time, top line results outshined analysts by $ 13.17 million or 1.84 percent.
Stock Performance
Shares of PRA Health Sciences, Inc. traded up $ 3.61 or 3.63 percent on Tuesday, reaching $ 103.13 with volume of 164.40 thousand shares. PRA Health Sciences, Inc. has traded high as $ 104.56 and has cracked $ 101.05 on the downward trend
According to the previous trading day, closing price of $ 103.13, representing a 69.63 % increase from the 52 week low of $ 58.67 and a 12.25 % decrease over the 52 week high of $ 113.41.
The company has a market capital of $ 6.60 billion and is part of the Healthcare sector and Diagnostics & Research industry.
PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
